Evaluating the Impact of Gene Polymorphism on Polycystic Ovary Syndrome: a Comprehensive Meta-analysis and Power Assessment

Overview

Journal J Turk Ger Gynecol Assoc

Publisher Galenos Publishing House

Specialty Gynecology & Obstetrics

Date 2024 Dec 11

PMID 39658874

Authors

Sheena Mariam Thomas

Ramakrishnan Veerabathiran

Affiliations

Soon will be listed here.

Abstract

Objective: Polycystic ovary syndrome (PCOS) is prevalent among reproductive-aged women and is categorized by hormonal imbalances, irregular menstrual cycles, and challenges with fertility. PCOS affects approximately 3.6% of women globally, with prevalence varying by region. The luteinizing hormone/choriogonadotropin receptor () gene, which encodes the , has been implicated in PCOS pathophysiology. This study investigated the association between the gene polymorphism rs2293275 and PCOS through a meta-analysis.

Material And Methods: An extensive literature review was carried out using Embase, PubMed, and Google Scholar databases to identify research studies exploring the association between gene variants and PCOS. The review was conducted based on the PRISMA checklist. Eligible case-control studies from 2016 to 2024 were chosen based on predefined criteria. Quantitative data analysis was performed using MetaGenyo software, employing a significance threshold of p<0.05. Odds ratios (OR) and confidence intervals (CI) were calculated to evaluate the relationships. G*Power 3.1 software was employed for statistical power analysis to assess the study's strength. The meta-analysis explored the link between gene variant rs2293275 and PCOS across diverse ethnic groups and genetic models.

Results: Analyzing data from 10 studies involving 1,431 PCOS cases and 1,317 controls, the findings revealed no significant associations in most genetic models: allele (OR: 0.89, 95% CI: 0.54-1.49), dominant (OR: 0.74, 95% CI: 0.47-1.18), recessive (OR: 0.80, 95% CI: 0.41-1.57), and over-dominant (OR: 1.13, 95% CI: 0.69-1.85). Subgroup analyses by ethnicity (Arabs, Asians, Caucasians) consistently showed no significant correlations, except a protective effect in Caucasians (OR: 0.57, 95% CI: 0.34-0.95) in the AA vs. aa comparison. Sensitivity analyses confirmed robustness, and there was no indication of publication bias. Power analysis validated adequate sample sizes, and protein-protein interaction networks underscored biological relevance.

Conclusion: The meta-analysis concluded that no significant connection was observed between the gene variant rs2293275 and the risk of PCOS among different populations. This suggests a complexity in PCOS etiology and indicating that may not be a significant genetic marker for PCOS. Future research should explore other genetic and environmental factors contributing to PCOS, emphasizing the importance of genetic and ethnic variability in such studies.

References

Chaudhary H, Patel J, Jain N, Joshi R . The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. J Ovarian Res. 2021; 14(1):125. PMC: 8466925. DOI: 10.1186/s13048-021-00879-w. View

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 34(2):388. PMC: 6343464. DOI: 10.1093/humrep/dey363. View

Zhang J, Zhan L, Zhao M, Wang J, Xie F, Xu Z . Role of EGFR expressed on the granulosa cells in the pathogenesis of polycystic ovarian syndrome. Front Endocrinol (Lausanne). 2022; 13:971564. PMC: 9691951. DOI: 10.3389/fendo.2022.971564. View

Makhdoomi M, Shah I, Rashid R, Rashid A, Singh S, Shah Z . Effect Modification of LHCGR Gene Variant (rs2293275) on Clinico-Biochemical Profile, and Levels of Luteinizing Hormone in Polycystic Ovary Syndrome Patients. Biochem Genet. 2023; 61(4):1418-1432. DOI: 10.1007/s10528-022-10327-z. View

Capalbo A, Sagnella F, Apa R, Fulghesu A, Lanzone A, Morciano A . The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2·7-fold increased risk of polycystic ovary syndrome in a Sardinian population. Clin Endocrinol (Oxf). 2012; 77(1):113-9. DOI: 10.1111/j.1365-2265.2012.04372.x. View

Lu X, Yan Z, Cai R, Khor S, Wu L, Sun L . Pregnancy and Live Birth In Women With Pathogenic LHCGR Variants Using Their Own Oocytes. J Clin Endocrinol Metab. 2019; 104(12):5877-5892. DOI: 10.1210/jc.2019-01276. View

Waterbury J, Teves M, Gaynor A, Han A, Mavodza G, Newell J . The PCOS GWAS Candidate Gene Influences Theca Cell Expression of , , and Androgen Production. J Endocr Soc. 2022; 6(7):bvac078. PMC: 9155636. DOI: 10.1210/jendso/bvac078. View

Jaseem Khan M, Ullah A, Basit S . Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Appl Clin Genet. 2020; 12:249-260. PMC: 6935309. DOI: 10.2147/TACG.S200341. View

Deswal R, Nanda S, Dang A . Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome. Syst Biol Reprod Med. 2019; 65(5):400-408. DOI: 10.1080/19396368.2019.1595217. View

10.

Patel S . Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018; 182:27-36. DOI: 10.1016/j.jsbmb.2018.04.008. View

11.

Kawai T, Richards J, Shimada M . The Cell Type-Specific Expression of Lhcgr in Mouse Ovarian Cells: Evidence for a DNA-Demethylation-Dependent Mechanism. Endocrinology. 2018; 159(5):2062-2074. PMC: 5905396. DOI: 10.1210/en.2018-00117. View

12.

Idicula-Thomas S, Gawde U, Bhaye S, Pokar K, Bader G . Meta-analysis of gene expression profiles of lean and obese PCOS to identify differentially regulated pathways and risk of comorbidities. Comput Struct Biotechnol J. 2020; 18:1735-1745. PMC: 7352056. DOI: 10.1016/j.csbj.2020.06.023. View

13.

Thathapudi S, Kodati V, Erukkambattu J, Addepally U, Qurratulain H . Association of luteinizing hormone chorionic gonadotropin receptor gene polymorphism (rs2293275) with polycystic ovarian syndrome. Genet Test Mol Biomarkers. 2015; 19(3):128-32. PMC: 4361359. DOI: 10.1089/gtmb.2014.0249. View

14.

Jamshidi M, Mohammadi Pour S, Bahadoram M, Mahmoudian-Sani M, Saeedi Boroujeni A . Genetic polymorphisms associated with polycystic ovary syndrome among Iranian women. Int J Gynaecol Obstet. 2020; 153(1):33-44. DOI: 10.1002/ijgo.13534. View

15.

El-Shal A, Zidan H, Rashad N, Abdelaziz A, Harira M . Association between genes encoding components of the Leutinizing hormone/Luteinizing hormone-choriogonadotrophin receptor pathway and polycystic ovary syndrome in Egyptian women. IUBMB Life. 2015; 68(1):23-36. DOI: 10.1002/iub.1457. View

16.

Akram Husain R, Ramakrishnan V . Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies. Ann Glob Health. 2016; 81(5):675-83. DOI: 10.1016/j.aogh.2015.08.026. View

17.

Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W . Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021; 12:741764. PMC: 8564180. DOI: 10.3389/fendo.2021.741764. View

18.

Mann O, Kong C, Lucas E, Brosens J, Hanyaloglu A, Brighton P . Expression and function of the luteinizing hormone choriogonadotropin receptor in human endometrial stromal cells. Sci Rep. 2022; 12(1):8624. PMC: 9124191. DOI: 10.1038/s41598-022-12495-9. View

19.

Bassiouny Y, Rabie W, Ahmed Hassan A, Darwish R . Association of the luteinizing hormone/choriogonadotropin receptor gene polymorphism with polycystic ovary syndrome. Gynecol Endocrinol. 2014; 30(6):428-30. DOI: 10.3109/09513590.2014.895982. View

20.

Casarini L, Santi D, Brigante G, Simoni M . Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocr Rev. 2018; 39(5):549-592. DOI: 10.1210/er.2018-00065. View